Biotechnology
Critical need for doctors to counsel couples on potential genetic burden in offspring of older dads
MANILA, Philippines, May 26, 2024 /PRNewswire/ -- An increasing trend of older fatherhood is potentially creating a global genetic disaster with devastating health consequences for offspring. A major conference of human reproductive health in the Philippines will hear of mounting evidence that...
2024-05-26 15:59
2751
YS Biopharma Announces Name Change to LakeShore Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-05-24 19:30
2093
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...
2024-05-24 17:36
2687
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website
* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...
2024-05-24 13:00
2391
Antengene To Present One Oral and Four Abstracts at ASCO 2024
* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer * Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor(XPO1 Inh...
2024-05-24 08:30
2966
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...
2024-05-24 08:00
2433
ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE
Operation aims to strengthen the Company's financial position and maintain growth strategy SAO PAULO, May 24, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3), a leading oncology company headquartered inLatin America, has announced that the enterprise has approved a capital increase ofR$ 1.5 bil...
2024-05-24 06:41
2092
Providence and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics
CALGARY, AB and TORONTO, May 23, 2024 /PRNewswire/ -- Providence Therapeutic Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the development of vaccines and therapeutics, and the Ontario Institute for Cancer Research (OICR),Ontario's largest...
2024-05-23 21:05
1406
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
SINGAPORE, May 23, 2024 /PRNewswire/ -- MediThinQ, the Korean startup pioneering extended reality (XR) wearable displays for surgical applications, unveils its groundbreaking SCOPEYE 3D Micro Surgery Solution. This innovative microsurgery solution leverages the latest Eyes Up Display technology t...
2024-05-23 10:00
14233
Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference
Corporate presentation scheduled for Tuesday, 04 June 2024 at 4:00 PM PT SAN DIEGO and SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- Bionoxx Inc., an innovative biotech company developing neutrophil-directed T cell modulation technology, announced today it will unveil its novel immunomodulator...
2024-05-23 08:00
2008
Further CYP-001 GvHD Clinical Data Published in Nature Medicine
Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60% MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to an...
2024-05-23 07:53
1776
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016
SUZHOU, China, May 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (JSKN016-101) of JSKN016, a novel bispecific antibody-drug conjugate (ADC) targeting HER3 and TROP2, in the treatment of ...
2024-05-22 09:16
2130
YS Biopharma Announces Results of Extraordinary General Meeting
GAITHERSBURG, Md., May 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-05-22 04:15
3204
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
2024-05-21 17:35
1848
BGI Team Successfully Reaches the Summit of Mount Everest
Sends the world's first ultrasound image and EEG data from the top of the world SHENZHEN, China, May 21, 2024 /PRNewswire/ -- BGI Group Chairman and Co-Founder,Wang Jian, and a scientific team from BGI today reached the summit of Mount Everest (Qomolangma) at 8,848.86 meters and, using handheld u...
2024-05-21 16:41
1656
Proto Axiom Launches The Challenger Summit: Australia's Premier Biotech Pitch-Event with over $250,000 in Grant Financing
SYDNEY, May 21, 2024 /PRNewswire/ -- Proto Axiom, Australia's first true biotech incubator, is thrilled to announce the launch of The Challenger Summit. The Challenger Summit will provide a unique platform for researchers to showcase their innovative biotech solutions, competing for over$250,000 ...
2024-05-21 11:28
1945
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...
2024-05-21 08:55
2474
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
BORDEAUX, France, May 20, 2024 /PRNewswire/ -- TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1] Par...
2024-05-20 14:30
1828
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-05-20 08:20
2434
LiveSpo Pharma Emerges as Vietnam's Pioneer at Vitafoods Europe 2024, Unveiling Groundbreaking Research and Product Development to Reduce Antibiotic Use in Digestive and Respiratory Care
HANOI, Vietnam, May 17, 2024 /PRNewswire/ -- LiveSpo Pharma is the first Vietnamese entity to report on clinical studies at Vitafoods Europe 2024, held inGeneva, Switzerland. LiveSpo Pharma showcased its range of high-concentration, multi-strain liquid medical probiotics products, affirming the ...
2024-05-17 18:33
4836
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
6832
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4917
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4673
